Global safety in adalimumab (HUMIRA®) rheumatoid arthritis clinical trials.

被引：0
|
作者：
Schiff, MH
Burmester, GR
Pangan, AL
Kupper, H
Spencer-Green, GT
机构：
[1] Denver Arthrit Clin PC, Denver, CO USA
[2] Univ Klinikum, Charite, Berlin, Germany
[3] Abbott Labs, Abbott Pk, IL 60064 USA
[4] Abbott Labs, Ludwigshafen, Germany
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S562 / S562
页数：1
相关论文
共 50 条
  • [1] Serious infections in patients with rheumatoid arthritis who participated in adalimumab (HUMIRA®) clinical trials.
    Kent, J
    Pangan, A
    Spencer-Green, G
    Szczerbak, N
    Sasso, E
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S548 - S548
  • [2] Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
    Schiff, M. H.
    Burmester, G. R.
    Kent, J. D.
    Pangan, A. L.
    Kupper, H.
    Fitzpatrick, S. B.
    Donovan, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (07) : 889 - 894
  • [3] Long-term safety of adalimumab (humira®) in worldwide rheumatoid arthritis clinical trials
    Schiff, MH
    Burmester, GR
    Pangan, A
    Kupper, H
    Spencer-Green, GT
    [J]. RHEUMATOLOGY, 2005, 44 : I70 - I71
  • [4] Safety of adalimumab (HUMIRA®) in global clinical trials of patients with early vs. long-standing rheumatoid arthritis (RA)
    Schiff, MH
    Burmester, GR
    Pangan, AL
    Kupper, H
    Spencer-Green, GT
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 422 - +
  • [5] Adalimumab (Humira) for rheumatoid arthritis
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1153): : 25 - 27
  • [6] Adalimumab (Humira) for the Treatment of Rheumatoid Arthritis
    Welch, Beth
    [J]. AMERICAN FAMILY PHYSICIAN, 2008, 78 (12) : 1406 - +
  • [7] Rates of serious infections from adalimumab (HUMIRA®) clinical trials of patients with Rheumatoid Arthritis (RA)
    Kent, J. D.
    Pangan, A. L.
    Spencer-Green, G. T.
    Szczerbak, N.
    Sasso, E. H.
    [J]. RHEUMATOLOGY, 2006, 45 : I42 - I43
  • [8] Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA™, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials.
    Granneman, RG
    Zhang, YM
    Noertersheuser, PA
    Velagapudi, RB
    Awni, WM
    Locke, CS
    Fischkoff, SA
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S140 - S141
  • [9] Long-Term Safety of Tocilizumab in Rheumatoid Arthritis Clinical Trials.
    Genovese, Mark C.
    Sebba, Anthony
    Rubbert-Roth, Andrea
    Scali, Juan
    Zilberstein, Moshe
    Thompson, Liz
    van Vollenhoven, Ronald F.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S866 - S866
  • [10] Safety and efficacy of adalimumab (Humira®) in patients with rheumatoid arthritis in Germany:: React study
    Burmester, GR
    Alten, R
    Tony, H
    Liman, W
    Gromnica-Ihle, E
    Stierle, HE
    Zeidler, H
    Von Hinüber, U
    Kellner, H
    Häntzschel, H
    Lemma, E
    Zeise, E
    Kupper, H
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 266 - 266
12345